Atlas Venture Fund XII, L.P. - 15 Jul 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
10%+ Owner
Signature
Atlas Venture Fund XII, L.P. By: Atlas Venture Associates XII, L.P., Its: General Partner By: Atlas Venture Associates XII, LLC, Its General Partner, By: /s/ Ommer Chohan
Issuer symbol
JBIO
Transactions as of
15 Jul 2022
Net transactions value
$0
Form type
4
Filing time
19 Jul 2022, 17:28:43 UTC
Previous filing
04 Apr 2022
Next filing
07 Aug 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Other $0 -310,388 -12% $0.000000 2,327,909 15 Jul 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Atlas Venture Fund XII, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XII pursuant to Rule 10b5-1 on November 24, 2021.